Compliance Rate

Compliance Rate 100.0%
Compliant submissions 1
Incompliant submissions 0
Total trials 1

My Organizations' Clinical Trials

Showing 1500 of 2051 entries
View as:

Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)

Phase: N/A Priority: Normal
NCT ID: NCT00777959 Org: User:
Start: 10/31/08 End: 06/30/11 Due: 06/30/12

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Phase: N/A Priority: Normal
NCT ID: NCT04152863 Org: User:
Start: 06/05/20 End: 07/12/23 Due: 07/12/24

MK0524A Clinical Efficacy Study (0524A-026)(COMPLETED)

Phase: N/A Priority: Normal
NCT ID: NCT00533312 Org: User:
Start: 04/30/05 End: 01/31/07 Due: 01/31/08

Study of Posaconazole in the Treatment of Invasive Fungal Infections (Study P02095)

Phase: N/A Priority: Normal
NCT ID: NCT00034632 Org: User:
Start: 04/30/01 End: 03/31/07 Due: 03/31/08

Study of Denufosol Tetrasodium in Patients With Cystic Fibrosis Lung Disease

Phase: N/A Priority: Normal
NCT ID: NCT00103714 Org: User:
Start: 01/31/05 End: 08/31/05 Due: 08/31/06

A Study of Denufosol Tetrasodium Intravitreal Injection in Subjects With Post Cataract Extraction Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT00135655 Org: User:
Start: 08/31/05 End: - Due: -

A Study to Assess the Safety and Efficacy of MK8245 in Patients With Type 2 Diabetes Mellitus and Inadequate Glycemic Control (MK8245-005 AM2)

Phase: N/A Priority: Normal
NCT ID: NCT00846391 Org: User:
Start: 12/31/08 End: 08/31/09 Due: 08/31/10

A Study to Evaluate Efficacy and Safety of Extended-Release Niacin + Laropiprant + Simvastatin in Participants With Primary Hypercholesterolemia or Mixed Dyslipidemia (MK-0524B-118)

Phase: N/A Priority: Normal
NCT ID: NCT01294683 Org: User:
Start: 02/04/11 End: 01/17/12 Due: 01/17/13

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

Phase: N/A Priority: Normal
NCT ID: NCT06717347 Org: User:
Start: 01/27/25 End: 03/29/32 Due: 03/29/33

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

Phase: N/A Priority: Normal
NCT ID: NCT04895358 Org: User:
Start: 06/18/21 End: 12/18/27 Due: 12/18/28

A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014)

Phase: N/A Priority: Normal
NCT ID: NCT00985166 Org: User:
Start: 08/31/00 End: 05/31/03 Due: 05/31/04

Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)

Phase: N/A Priority: Normal
NCT ID: NCT04949256 Org: User:
Start: 07/28/21 End: 01/31/27 Due: 01/31/28

Safety of Org 34517 900 mg in Patients Who Received Org 34517 in a Previous Trial (Study 28133/P05842)

Phase: N/A Priority: Normal
NCT ID: NCT00844922 Org: User:
Start: 09/30/05 End: 06/30/06 Due: 06/30/07

Broad Spectrum HPV Vaccine Dose Ranging Study (V502-001)

Phase: N/A Priority: Normal
NCT ID: NCT00260039 Org: User:
Start: 12/31/05 End: 08/31/07 Due: 08/31/08

Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)

Phase: N/A Priority: Normal
NCT ID: NCT03546842 Org: User:
Start: 06/29/18 End: 01/29/19 Due: 01/29/20

Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)

Phase: N/A Priority: Normal
NCT ID: NCT02739997 Org: User:
Start: 04/08/16 End: 07/28/17 Due: 07/28/18

MK0767 and Sulfonylurea Combination Study (0767-027)

Phase: N/A Priority: Normal
NCT ID: NCT00543491 Org: User:
Start: 05/31/03 End: 12/31/03 Due: 12/31/04

Efficacy and Safety of Navarixin (SCH 527123) in Participants With Allergen-Induced Asthma (P05363)

Phase: N/A Priority: Normal
NCT ID: NCT00688467 Org: User:
Start: 06/01/08 End: 03/01/09 Due: 03/01/10

Post Marketing Surveillance: Newly Diagnosed Glioblastoma Multiforme Treated With Radiotherapy/Temozolomide and Adjuvant Temozolomide (Study P04739)

Phase: N/A Priority: Normal
NCT ID: NCT00704808 Org: User:
Start: 05/31/06 End: 12/31/08 Due: 12/31/09

Upper GI Handling of Branded vs. Generic Alendronate

Phase: N/A Priority: Normal
NCT ID: NCT00400530 Org: User:
Start: 12/31/05 End: - Due: -

Safety, Pharmacodynamics, and Pharmacokinetics of Different Dosing Regimens of MK-8266 in Participants With Hypertension (MK-8266-008)

Phase: N/A Priority: Normal
NCT ID: NCT01244035 Org: User:
Start: 08/19/10 End: 12/23/10 Due: 12/23/11

Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)

Phase: N/A Priority: Normal
NCT ID: NCT06651281 Org: User:
Start: 11/25/24 End: 12/17/37 Due: 12/17/38

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Phase: N/A Priority: Normal
NCT ID: NCT06966700 Org: User:
Start: 06/19/25 End: 02/04/35 Due: 02/04/36

A Switch to Doravirine/Islatravir (DOR/ISL) in Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Who Are Virologically Suppressed on Antiretroviral Therapy (ART) (MK-8591A-051)

Phase: N/A Priority: Normal
NCT ID: NCT05631093 Org: User:
Start: 02/20/23 End: 07/11/28 Due: 07/11/29

A Clinical Study of MK-6552 and Modafinil in Healthy Men (MK-6552-005)

Phase: N/A Priority: Normal
NCT ID: NCT06665230 Org: User:
Start: 09/20/23 End: 11/20/23 Due: 11/20/24